Decipher Biosciences

Executive Summary

Decipher Biosciences, operating under Veracyte, is a commercial-stage diagnostics company specializing in genomic tests for urologic cancers, primarily Decipher Prostate and Decipher Bladder. These tests analyze tissue samples to provide prognostic and predictive insights, enabling personalized treatment decisions for prostate and bladder cancer patients. As part of Veracyte, Decipher benefits from a established commercial infrastructure and reimbursement coverage. The company's tests are supported by robust clinical evidence and are increasingly incorporated into clinical guidelines, driving adoption. The Decipher Prostate test is well-established, while Decipher Bladder represents a significant growth opportunity as it addresses a high unmet need in bladder cancer management. With a valuation of approximately $2.56 billion, Decipher is positioned for continued market expansion, particularly through broader insurance coverage and guideline inclusions. However, competition from other genomic tests and reliance on reimbursement dynamics pose risks. Overall, Decipher Biosciences is a key player in precision oncology diagnostics with a strong product portfolio and growth trajectory.

Upcoming Catalysts (preview)

• Q3 2026Decipher Bladder expanded Medicare coverage decision70% success
• Q4 2026Inclusion of Decipher Prostate in updated NCCN guidelines for prostate cancer80% success
• Q2 2026Publication of prospective clinical trial data supporting Decipher Bladder utility60% success